Latest Lipid Therapeutics Stories
HEIDELBERG, Germany, June 22, 2011 /PRNewswire/ -- - Primary Endpoint Met Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis. LT-02 is a controlled release formulation of phosphatidylcholine that has been specifically designed to treat ulcerative colitis by improving the barrier...
- Remarkable; prodigious.
- Audacious; gutsy.
- Completely; extremely.
- Audaciously; boldly.
- Impressively great in size; enormous; extraordinary.